EPISODE · Jul 12, 2013 · 11 MIN
A Clear Answer to the Wrong Question
from Journal of Clinical Oncology (JCO) Podcast
The AVAPERL trial reveals a significant improvement in progression-free survival with the combination of pemetrexed/bevacizumab compared with bevacizumab alone as maintenance therapy for advanced non- small-cell lung cancer, but the clinically relevant endpoint remains overall survival.
Embed this episode
NOW PLAYING
A Clear Answer to the Wrong Question
0:00
11:53
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Journal of Clinical Oncology (JCO) Podcast?
This episode is 11 minutes long.
When was this Journal of Clinical Oncology (JCO) Podcast episode published?
This episode was published on July 12, 2013.
Can I download this Journal of Clinical Oncology (JCO) Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!